Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

NCT02053636 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02053636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02053636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
April 4, 2017
Enrollment
76 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer